WO2000073338A8 - Compositions and methods for the therapy, diagnosis and monitoring of breast cancer - Google Patents

Compositions and methods for the therapy, diagnosis and monitoring of breast cancer

Info

Publication number
WO2000073338A8
WO2000073338A8 PCT/US2000/014845 US0014845W WO0073338A8 WO 2000073338 A8 WO2000073338 A8 WO 2000073338A8 US 0014845 W US0014845 W US 0014845W WO 0073338 A8 WO0073338 A8 WO 0073338A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
breast cancer
compositions
diagnosis
therapy
Prior art date
Application number
PCT/US2000/014845
Other languages
French (fr)
Other versions
WO2000073338A1 (en
WO2000073338A9 (en
Inventor
Gary Richard Fanger
Ronald C Hendrickson
Raymond L Houghton
Steven G Reed
Original Assignee
Corixa Corp
Gary Richard Fanger
Ronald C Hendrickson
Raymond L Houghton
Steven G Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Gary Richard Fanger, Ronald C Hendrickson, Raymond L Houghton, Steven G Reed filed Critical Corixa Corp
Priority to EP00939407A priority Critical patent/EP1185557A1/en
Priority to JP2001500662A priority patent/JP2003502028A/en
Priority to AU54496/00A priority patent/AU5449600A/en
Priority to CA002375049A priority patent/CA2375049A1/en
Publication of WO2000073338A1 publication Critical patent/WO2000073338A1/en
Publication of WO2000073338A8 publication Critical patent/WO2000073338A8/en
Publication of WO2000073338A9 publication Critical patent/WO2000073338A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammaglobin epitopes, or antibodies or T cells thereto, and may be used, for example, for the prevention and treatment of breast cancer. Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.
PCT/US2000/014845 1999-05-28 2000-05-26 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer WO2000073338A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00939407A EP1185557A1 (en) 1999-05-28 2000-05-26 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
JP2001500662A JP2003502028A (en) 1999-05-28 2000-05-26 Compositions and methods for treating, diagnosing and monitoring breast cancer
AU54496/00A AU5449600A (en) 1999-05-28 2000-05-26 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
CA002375049A CA2375049A1 (en) 1999-05-28 2000-05-26 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13652899P 1999-05-28 1999-05-28
US60/136,528 1999-05-28
US13704899P 1999-06-01 1999-06-01
US60/137,048 1999-06-01

Publications (3)

Publication Number Publication Date
WO2000073338A1 WO2000073338A1 (en) 2000-12-07
WO2000073338A8 true WO2000073338A8 (en) 2001-05-25
WO2000073338A9 WO2000073338A9 (en) 2002-01-24

Family

ID=26834387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014845 WO2000073338A1 (en) 1999-05-28 2000-05-26 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer

Country Status (5)

Country Link
EP (1) EP1185557A1 (en)
JP (1) JP2003502028A (en)
AU (1) AU5449600A (en)
CA (1) CA2375049A1 (en)
WO (1) WO2000073338A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044859A1 (en) * 1996-08-19 2003-03-06 Henslee Jerry G. Reagents and methods useful for detecting diseases of the breast
WO2002053017A2 (en) * 2001-01-08 2002-07-11 Corixa Corporation Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
CN108864272B (en) * 2018-07-03 2021-04-27 中国人民解放军军事科学院军事医学研究院 Mammaglobin A epitope and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922836A (en) * 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5668267A (en) * 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
AU728777B2 (en) * 1996-01-11 2001-01-18 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
EP0856010A1 (en) * 1996-08-19 1998-08-05 Abbott Laboratories Mammaglobin, antibodies thereto, and their use for detecting diseases of the breast
AU9804198A (en) * 1997-10-16 1999-05-03 Incyte Pharmaceuticals, Inc. Mammoglobin homolog

Also Published As

Publication number Publication date
WO2000073338A1 (en) 2000-12-07
EP1185557A1 (en) 2002-03-13
WO2000073338A9 (en) 2002-01-24
JP2003502028A (en) 2003-01-21
AU5449600A (en) 2000-12-18
CA2375049A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
WO2003028531A3 (en) Detection of tumor rna in plasma and serum
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ES2138729T3 (en) DIAGNOSTIC METHODS OF PREECLAMPSIA.
WO2002057741A3 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2000000615A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2003001183A3 (en) Methods for detecting and monitoring cox-2 rna in plasma and serum
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000073338A8 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2002053017A3 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
WO2002072752A3 (en) Forms of prostate specific antigens and methods for their detection
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
ENP Entry into the national phase

Ref document number: 2375049

Country of ref document: CA

Ref country code: CA

Ref document number: 2375049

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 500662

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 54496/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 515976

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000939407

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/24-24/24, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000939407

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000939407

Country of ref document: EP